ELISA Kit for Wingless Type MMTV Integration Site Family, Member 3A (WNT3A)

Format

48T, 96T, 96T×5, 96T×10, 96T×100

Detection range

0.156-10ng/mL

Application

Enzyme-linked immunosorbent assay for Antigen Detection.

Organism species

Homo sapiens (Human)

Sensitivity

The minimum detectable dose of this kit is typically less than 0.067ng/mL

Sample type

tissue homogenates, cell lysates, cell culture supernates and other biological fluids

Assay length

3h

Method

Double-antibody Sandwich

Test principle

The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Wingless Type MMTV Integration Site Family, Member 3A (WNT3A). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Wingless Type MMTV Integration Site Family, Member 3A (WNT3A). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Wingless Type MMTV Integration Site Family, Member 3A (WNT3A), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Wingless Type MMTV Integration Site Family, Member 3A (WNT3A) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

Alternative Names

Item Name

Wingless Type MMTV Integration Site Family, Member 3A

Research Area

Signal transduction;

Reference

Gelatin device for the delivery of growth factors involved in endochondral ossification;Secreted Frizzled-Related Protein-2 Inhibits Doxorubicin Induced Apoptosis Mediated Through the Akt-mTOR Pathway in Soleus Muscle;Eribulin Treatment Induces High Expression of miR-195 and Inactivates the Wnt/β-catenin Signaling Pathway in Triple-negative Breast Cancer;